Literature DB >> 8241949

Signal transduction in the erythropoietin receptor system.

D M Wojchowski1, T C He.   

Abstract

Developing erythroid cells require the glycoprotein hormone, erythropoietin (EPO) as an activator of the rapid proliferation of early proerythroblasts (colony forming units-erythroid [CFU-e]), and subsequently as an activator of late erythroid gene expression. Activation of these growth and differentiation events proceeds from the binding of EPO at its transmembrane receptor (Class I cytokine receptor), to the engagement of a complex set of signaling pathways. Studies of reconstituted activities of the cloned EPO receptor in transfected hematopoietic cell lines have served well in identifying receptor domains and downstream mediators involved in proliferative signaling. Extracellular domains have been defined which contribute to ligand binding, receptor processing and transport, and possible dimerization. Cytosolic regions have been delineated which mediate induced mitogenesis, early gene transcription, activated protein tyrosine phosphorylation, down modulation of EPO- and granulocyte-macrophage colony-stimulating factor (GM-CSF)-induced proliferation, and direct association with PI3- and JAK-2 kinases. These newly defined properties begin to align the EPO receptor mechanistically with growth factor receptors (GFR) which encode, or likewise associate with, regulated protein tyrosine kinases including the Class II cytokine receptors for interferons alpha/beta and gamma. An improved understanding of factors which mediate EPO-induced late erythroid gene activation also is emerging. These factors and pathways may be distinct from those associated with EPO-induced proliferation and may involve induced increases in cellular Ca++, cAMP and arachidonic acid, as well as the modulation of GATA-1, and/or SCL. Attributes of model systems used in studies of the role of EPO in late erythroid differentiation also are considered.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8241949     DOI: 10.1002/stem.5530110505

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  7 in total

1.  GM-CSF induces expression of soluble VEGF receptor-1 from human monocytes and inhibits angiogenesis in mice.

Authors:  Tim D Eubank; Ryan Roberts; Michelle Galloway; Yijie Wang; David E Cohn; Clay B Marsh
Journal:  Immunity       Date:  2004-12       Impact factor: 31.745

2.  Three Tyrosine Residues in the Erythropoietin Receptor Are Essential for Janus Kinase 2 V617F Mutant-induced Tumorigenesis.

Authors:  Fumihito Ueda; Kenji Tago; Hiroomi Tamura; Megumi Funakoshi-Tago
Journal:  J Biol Chem       Date:  2016-12-20       Impact factor: 5.157

Review 3.  Erythropoietin molecules to treat acute ischemic stroke: a translational dilemma!

Authors:  Paul A Lapchak
Journal:  Expert Opin Investig Drugs       Date:  2010-10       Impact factor: 6.206

Review 4.  Use of high-dose erythropoietin for repair after injury: A comparison of outcomes in heart and kidney.

Authors:  Glenda C Gobe; Christudas Morais; David A Vesey; David W Johnson
Journal:  J Nephropathol       Date:  2013-07-01

5.  Pregnancy alters the proliferation and apoptosis of mouse splenic erythroid lineage cells and leukocytes.

Authors:  Michelle T Norton; Karen A Fortner; Peyman Bizargity; Elizabeth A Bonney
Journal:  Biol Reprod       Date:  2009-04-15       Impact factor: 4.285

6.  Potential of Novel EPO Derivatives in Limb Ischemia.

Authors:  Dhiraj Joshi; Janice Tsui; Rebekah Yu; Xu Shiwen; Sadasivam Selvakumar; David J Abraham; Daryll M Baker
Journal:  Cardiol Res Pract       Date:  2012-02-22       Impact factor: 1.866

7.  Erythropoietin in the intensive care unit: beyond treatment of anemia.

Authors:  Nimesh Sa Patel; Massimo Collino; Muhammad M Yaqoob; Christoph Thiemermann
Journal:  Ann Intensive Care       Date:  2011-09-23       Impact factor: 6.925

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.